To provide insights for clinicians and parents, and to inform an upcoming clinical trial, a team led by Lauren E. Kelly, PhD, associate professor of pharmacology and therapeutics in the Rady Faculty of Health Sciences at the University of Manitoba, searched the medical literature to summarize existing knowledge about the potential benefits and harms of cannabis products in children with cancer.

Digging Deep in Clinical Trials to Test Cannabis Potency in Alleviating Cancer Symptoms

The investigators identified 19 unique studies with a total of 1,927 participants with cancer: eight retrospective chart reviews, seven randomized controlled trials, two open‐label studies, and two case reports. The products studied included medical-grade cannabinoids (such as the prescription drug nabilone), synthetic cannabinoids, and unspecified cannabis herbal extracts. Products were most commonly used to manage chemotherapy‐induced nausea and vomiting.

Advertisement

In the randomized controlled trials, patients who used cannabinoids were more likely to experience drowsiness, feeling high, dizziness, and dry mouth. Also, trial participants who received cannabinoids were almost four times more likely to drop from the study due to adverse events, compared with the control group who received placebo. Across all included studies, no serious cannabis‐related adverse events were reported.

Dr. Kelly and her colleagues noted that most studies did not adequately describe the types, dosing, frequencies, and routes of administration of cannabis products, and outcomes were mixed and reported in different ways.

“It was difficult to measure benefit across studies, given a range of different outcomes and study designs; however, in interventional studies with active control groups, cannabinoids performed better in managing nausea and vomiting. Data are lacking on cannabinoids’ effects on pain, mood, sleep, and health-related quality of life,” said Dr. Kelly.

Given that some children report benefits and some children experience adverse events, it is critical that more rigorous studies evaluating the effects of cannabinoids on children with cancer are conducted and shared with parents, patients, and the healthcare community.

Reference :

1. Cannabis and Cannabinoids (PDQ)-Health Professional Version – (https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq)
2. Systematic review and meta‐analysis of cannabinoids in palliative medicine- (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879974/)

Source: Eurekalert